NCT06636812 Losartan and Emotional Processing in Young People
| NCT ID | NCT06636812 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Oxford |
| Condition | Emotional Processing |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-07 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2024-03-07 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.
Eligibility Criteria
Inclusion Criteria: * Willing and able to provide informed consent (for 16 and 17 year olds: assent and parental/ legal guardian consent) * Non- or light-smoker (\< 5 cigarettes a day) * Ability to attend appointments in Oxford with reasonable travel costs * Ability/ willingness to provide GP contact details Exclusion Criteria: * Past or present DSM-5 axis-I diagnosis (based on SCID results at screening), especially severe psychiatric illness or alcohol or substance dependence * First-degree family member with severe psychiatric illness * CNS-medication last 6 weeks (including as part of another study) * Current blood pressure or other heart medication (especially aliskiren or beta blockers) * Diagnosis of intravascular fluid depletion or dehydration * Impaired kidney function (based on blood test at screening, cut-off 75 ml/min/1.73 m2) * Significant hyperkalaemia (level\>=6mEq/L in the absence of sample haemolysis will be considered significant hyperkalaemia) * Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions: DOI 10.1186/s12887-016-0633-7)) * Body weight below 35kg (as the lower dose of 25mg of losartan only indicated from 35kg) * Lifetime history of epilepsy or other neurological disease (e.g. ADHD, autism) * Lifetime history of angioedema, renal artery stenosis, valvular heart disease, recurrent postural/ orthostatic hypotension * Lifetime history ofsystemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. * Significant loss of hearing that is not corrected with a hearing device Insufficient written and/or spoken English skills * Women: pregnancy, breast-feeding
Contact & Investigator
Andrea Reinecke, PhD
PRINCIPAL INVESTIGATOR
University of Oxford
Frequently Asked Questions
Who can join the NCT06636812 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 20 Years, studying Emotional Processing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06636812 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06636812 currently recruiting?
Yes, NCT06636812 is actively recruiting participants. Contact the research team at andrea.reinecke@psych.ox.ac.uk for enrollment information.
Where is the NCT06636812 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT06636812 clinical trial?
NCT06636812 is sponsored by University of Oxford. The principal investigator is Andrea Reinecke, PhD at University of Oxford. The trial plans to enroll 60 participants.